Texas is currently home to 5037 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
Recruiting
Isunakinra - a potent Interleukin-1 receptor inhibitor - will be given to patients with solid tumors to determine safety and tolerability of three different doses. Isunakinra will then be combined with a PD-(L)1 inhibitor. Pharmacokinetics and Pharmacodynamic effects of monotherapy treatment as well as the combination will be evaluated.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2023
Locations: Baylor Charles A. Simmons Cancer Center, Dallas, Texas
Conditions: Solid Tumor, Adult
SEAM Trial: Sutureless End to End Anastomosis by Magnetic Compression
Recruiting
The objectives of this study are to determine the safety and effectiveness of the SFM Anastomosis Device when used to create a small bowel anastomosis for patients undergoing ileostomy reversal as compared with a propensity-matched historic control group of patients who underwent ileostomy reversal using a conventional closure technique (sutures or stapler).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2023
Locations: UT Health Science Center at Houston, Houston, Texas
Conditions: Retraction of Ileostomy
Randomized Trial of Enteral Vitamin D Supplementation in Infants < 28 Weeks Gestational Age or <1000 Grams Birth Weight
Recruiting
The objective of the study is to compare supplementation with vitamin D at 800 IU/day to usual care for the first 28 days after birth with respect to 25 (OH) vitamin D levels and indicators of likely or plausible effects of vitamin D supplementation on the function or structure of the lung, bones, immune system, and brain in extremely premature (EP) infants who are <28 weeks gestational age (GA) or <1000 grams of birth weight (BW). The study results will be analyzed as intention to treat Bayesia... Read More
Gender:
All
Ages:
Between 24 hours and 96 hours
Trial Updated:
02/18/2023
Locations: The University of Texas Medical Branch, Galveston, Texas
Conditions: Vitamin D Deficiency
Comparison of a Novel Ultrasound System Versus Standard Imaging Modalities
Recruiting
This is an observational study comparing a novel ultrasound-based imaging system (MAUI K3900) to standard-of-care (SoC) imaging systems used to guide and/or manage interventional radiologic procedures such as solid organ biopsies or lesion ablations.
Gender:
All
Ages:
All
Trial Updated:
02/17/2023
Locations: Texas Health Presbyterian Hospital, Dallas, Texas
Conditions: Image-Guided Biopsies and/or Ablations
Electrical Stimulation for Post Acute COVID-19 Syndrome
Recruiting
The purpose of the pilot study is to examine acceptability and proof of concept effectiveness of a wireless TENS technology to address PACS associated FM. Sample size (n=40) is convenient and designed to explore acceptability and feasibility. Eligible participants will be screened at the BCM Post-COVID-19 Clinic for inclusion criteria. Participants, who satisfy the inclusion and exclusion criteria and sign the informed consent form will be randomly assigned with ratio of 1:1 into two groups. One... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/17/2023
Locations: Baylor College of Medicine, Houston, Texas
Conditions: COVID-19, Muscle Weakness, Muscle Pain, Fatigue
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Recruiting
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: Local Institute, Amarillo, Texas
Conditions: Multiple Myeloma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors
Recruiting
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2023
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Castrate Resistant Prostate Cancer, NUT Carcinoma
Artificial Intelligence (AI) Cytopathology Trial
Recruiting
Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
02/15/2023
Locations: Memorial Hermann Hospital, Houston, Texas
Conditions: Pancreatic Solid Lesions
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
Recruiting
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/15/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
Recruiting
The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma
Gender:
All
Ages:
1 year and above
Trial Updated:
02/15/2023
Locations: University of Texas Southwestern Medical Center, Children's Health, Dallas, Texas
Conditions: Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Clinical and Electrographic Changes in Responsive Neurostimulation System (RNS) Patients With Acupuncture Treatment
Recruiting
The purpose of this study is to determine effects of Acupuncture on a Patient's mood and cognition,evaluate changes in clinically-reported seizure frequency and severity and analyze effects of Acupuncture on electrographic epileptiform activity stored by the RNS System
Gender:
All
Ages:
Between 15 years and 60 years
Trial Updated:
02/14/2023
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Epilepsy